University of Michigan Rogel Cancer Center | Strategic Alliance Partners

Connect with us:

Latest from University of Michigan Rogel Cancer Center

Dr. Vaishampayan on the Design of the PROBE Trial in RCC

May 13, 2022

Video

Ulka Nitin Vaishampayan, MBBS, discusses the design of the phase 3 PROBE trial in advanced renal cell carcinoma.

PROBE Trial in Progress to Understand Potential Benefits of Cytoreductive Nephrectomy in Metastatic RCC

April 20, 2022

Article

Ulka Nitin Vaishampayan, MBBS, discusses the intent of the PROBE trial, as well as updates regarding the KEYNOTE-564 trial and novel agents in kidney cancer treatment.

Dr. Vaishampayan on the PROBE Trial in Advanced RCC

April 05, 2022

Video

Ulka Nitin Vaishampayan, MBBS, discusses the intent of the phase 3 PROBE trial in advanced renal cell carcinoma.

Dr. Kim on Optimizing Individualized Treatment in Cancer Care

April 04, 2022

Video

Michelle Miran Kim, MD, discusses optimizing individualized treatment in cancer care.

Dr. Palmbos on the Utilization of Nivolumab Following Cystectomy in Muscle-Invasive Bladder Cancer

February 16, 2022

Video

Phillip Palmbos, MD, PhD, discusses the utilization of adjuvant nivolumab following cystectomy in high-risk, muscle-invasive bladder cancer.

Dr. Phillips on the Current Role of Ibrutinib in MCL

February 03, 2022

Video

Tycel Jovelle Phillips, MD, discusses the current role of ibrutinib in mantle cell lymphoma.

Dr. Phillips Discusses Ongoing Research With BTK Inhibitors in MCL

January 19, 2022

Video

Tycel Jovelle Phillips, MD, discusses ongoing research with BTK inhibitors in mantle cell lymphoma.

Dr. Yentz on Translating Data to Real-World Clinical Practice in RCC

January 18, 2022

Video

Sarah Elizabeth Yentz, MD, discusses translating data to real-world clinical practice in renal cell carcinoma.

Dr. Phillips Discusses Ongoing Trials in MCL

January 17, 2022

Video

Tycel Jovelle Phillips, MD, discusses ongoing trials in mantle cell lymphoma.

Dr. Phillips on Considering Age During Treatment Selection With BTK Inhibitors in MCL

January 10, 2022

Video

Tycel Jovelle Phillips, MD, discusses the importance of considering age during treatment selection for BTK inhibitors in mantle cell lymphoma.

Dr. Phillips on Navigating Treatment Selection With BTK Inhibitors in MCL

January 03, 2022

Video

Tycel Jovelle Phillips, MD, discusses navigating treatment selection with BTK inhibitors in mantle cell lymphoma.

Phillips Reflects on Lessons Learned With BTK Inhibitors in MCL

December 23, 2021

Podcast

Dr Phillips discusses the utility of ibrutinib, acalabrutinib, and zanubrutinib in mantle cell lymphoma, the impact of long-term follow-up data with ibrutinib, and findings from the phase 3 SYMPATICO trial that could shake up the treatment paradigm.

Dr. Qin on Treatment Considerations for Immunotherapy in NSCLC

December 06, 2021

Video

Angel Qin, MD, discusses treatment considerations for immunotherapy in patients with newly diagnosed non–small cell lung cancer.

Dr. Qin on Selecting Single-Agent Immunotherapy or Chemoimmunotherapy in NSCLC

December 03, 2021

Video

Angel Qin, MD, discusses selecting between single-agent immunotherapy or combination chemoimmunotherapy in non–small cell lung cancer.

Dr. Vaishampayan on the Future Directions for Second-Line Treatment in Urothelial Cancer

November 23, 2021

Video

Ulka Nitin Vaishampayan, MBBS, discusses future directions for second-line treatment in urothelial cancer.

Dr. Palmbos on Remaining Questions in Metastatic Urothelial Carcinoma

November 22, 2021

Video

Phillip L. Palmbos, MD, PhD, discusses remaining questions in metastatic urothelial carcinoma.

Investigators Set Their Sights on Optimizing Sequencing With Novel Therapies in GU Cancers

November 12, 2021

Article

Treatment selection and sequencing in genitourinary cancers, such as metastatic bladder cancer and metastatic renal cell carcinoma, have become more complicated and require nuanced decision making.

Dr. Yentz on Unmet Needs in Metastatic RCC

November 11, 2021

Video

Sarah Elizabeth Yentz, MD, discusses unmet needs in metastatic renal cell carcinoma.

Dr. Yentz on Navigating Frontline Treatment Selection in RCC

November 01, 2021

Video

Sarah Elizabeth Yentz, MD, discusses navigating frontline treatment selection in renal cell carcinoma.

Devimistat Plus Gemcitabine/Cisplatin Moves to Phase 2 Setting in Frontline Biliary Tract Cancer

September 03, 2021

Article

Devimistat in combination with gemcitabine and cisplatin has moved into the phase 2 portion of a phase 1b/2 trial studying the regimen as a first-line treatment for patients with locally advanced unresectable or metastatic biliary tract cancer.